anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The invention belongs to the filed of nanocomposite, in particular to a preparation method of yolk-eggshell nanocapsules with fluorescence and magnetism. Firstly, SPIO (Super Paramagnetic Iron Oxide) nanoparticles protected by hexadecyl trimethyl ammonium bromide molecules are prepared, then a silicon dioxide shell is formed on the outer layers of the nanoparticles with a sol-gel method, the thickness of the silicon dioxide shell can be adjusted through the addition of tetraethoxysilane. The outer layer of the silicon dioxide shell is wrapped with red fluorescent Y203:Eu, in this process, silicon dioxide is etched, thermal decomposition of urea thereof causes the solution thereof to be alkaline, OH- is used to etch the silicon dioxide, then centrifugation, drying and high-temperature calcination are performed, and finally, the nanocapsules with yolk-eggshell structures are formed. The method can realize the precise control of the magnetic performance, fluorescent performance, size of an internal cavity and shell thickness. Meanwhile, the obtained nanoparticles are good in dispersity and are uniform in size, and are suitable for the fields of biochemistry, clinical medicine and the like. The invention is simple, fast, safe, convenient in operation and good in repeatability, and has generality.
PROBLEM TO BE SOLVED: To obtain an agent for preventing or treating allergy to cedar pollen, containing a specific pectate lyase-related compound as an active ingredient, free from anxiety about adverse effects and capable of simply utilizing to persons who were already suffered by allergy to cedar pollen. SOLUTION: This preventing and treating agent contains a pectate lyase (A1 ), a protein (A2 ) having pectate lyase activity, a protein (A3 ) having pectate lyase activity, a protein (A3 ) having high homology at amino acid level with the protein or a peptide (A4 ) comprising a part thereof as an active ingredient. The enzyme A1 is obtained by culturing, e.g. vegetable putrefactive bacteria, especially E. carotovora Er. in the presence of pectic acid, secreting the enzyme A1 into a culture medium and purifying a supernatant of the culture medium by using an ion exchange method and gel permeation method. Furthermore, the medicine is preferably administered at a daily dose of 0.2-0.6mg/kg body as an active ingredient for the enzyme A1 in 1-4 portions.
BACKGROUND AND OBJECTIVE: Autoimmune hemolytic anemia (AIHA) is a rare but important cause of morbidity in pediatric hematology patients. Given its rarity, there is little high-quality evidence on which to base the investigation and management of pediatric AIHA. This scoping review aims to summarize the current evidence and highlight key gaps to inform future studies.
METHODS: This review searched MEDLINE and the Cochrane CENTRAL Trials Register from 2000 to November 03, 2023. Experimental and observational studies reporting AIHA diagnostic criteria, laboratory workup, or treatment/management in populations with at least 20% of patients ≤18 years were included.
RESULTS: Forty-three studies were included, with no randomized controlled trials identified. AIHA diagnostic criteria, diagnostic tests, and treatments were highly variable. First-line treatment approaches include corticosteroids, intravenous immunoglobulin, or both. Approaches to AIHA resistance to first-line therapy were widely variable between studies, but most commonly included rituximab and/or cyclosporine.
CONCLUSIONS: We identify a heterogenous group of observational studies into this complex, immune-mediated disorder. Standardized definitions and classifications are needed to guide collaborative efforts needed to study this rare disease. The work done by the CEREVANCE group provides an important paradigm for future studies.
FIELD: medicine. ^ SUBSTANCE: group of inventions relates to medicine and can be applied for treatment of liver failure. Transplant for treatment of liver failure includes heterogenic biocompatible biodegradable gel, which has total volume not less than 0.1 ml and the smallest linear size not less than 0.2 mm, pore size 30-500 mcm, total porosity 50-98%, implanted on it autologous progenitor cells of bone marrow after their cultivation in vitro and cultivated autologous liver cells, concentration of liver and bone marrow cells being 2ù106-15ù106 cells per 1 cm3 of heterogeneous gel and ratio of bone marrow cells to liver cells being from 1:1 to 1:4. In realisation of method of treating liver failure transplant is placed into parenchyma of liver and/or mesentery of small intestine. ^ EFFECT: group of inventions makes it possible to increase term of cell survival, activate their proliferation. ^ 4 cl
Compounds of methyl and ethyl scopolamine and sulphonic acid cation-exchange resins (including phenol-sulphonic acid, carboxylic-sulphonic acid and phosphonic-sulphonic acid resins) and having the formula <FORM:0914630/IV(a)/1> wherein R is a methyl or ethyl radical and A is the resin nucleus, are prepared by contacting an aqueous solution of a methyl or ethyl scopolamine salt, e.g. the hydrochloride or nitrate with the appropriate resin.  Specified resins are the sulphonated polymers of polyvinyl aryl compounds described in Specification 577,707 and the resins disclosed in U.S.A. Specifications 2,204,539, 2,338,159 and 2,729,607.  Reference is also made to a compound of methyl scopolamine and a carboxylic acid cation-exchange resin (IRC-50).  The Specification also refers to similar compounds of sulphonic acid cation-exchange resins and quinazolone derivatives of general formula <FORM:0914630/IV(a)/2> wherein X is a hydrogen or halogen atom, R is a C1-3 alkyl radical and R1 is a 2-alkyl substituted aryl radical and which may be prepared in the same way.  Specification 867,803 also is referred to.ALSO:Long acting anticholinergic compositions comprise, as active ingredients, a water-insoluble quaternary ammonium pseudo salt of seopolamine with a sulphonic acid cation-exchange resin having the general formula <FORM:0914630/VI/1> wherein R is a methyl or ethyl radical and A is a resin nucleous of a sulphonic acid cation-exchange resin and a synergistic amount of a quinazolone derivative of general formula <FORM:0914630/VI/2> wherein X represents a hydrogen or halogen atom, R represents a lower (C1-3) alkyl radical and R1 represents a 2-alkyl substituted aryl radical which is preferably also in the form of a resinate of the above type.  The compositions may take the form of a tablet, capsule, powder, liquid suspension or other orally administrable dosage form or the active materials may be incorporated into human or animal feedstuffs.  Optional additional active ingredients which may be included are phenobarbitol, anti-proteolytic agents, e.g. protamine sulphate, soy bean trypsin inhibitor, trypsin inhibitor from blood, anti-haemorrhagic and coagulent agents, e.g. thrombin, gelatin, Vitamin K, carboxymethyl-cellulose, methyl-cellulose, hormonal substances, e.g. cortisone, local an s thetics, e.g. procaine hydrochloride or benzocaine and carbonic anhydrase inhibitors, e.g. 2 - acetylamino - 1,3,4 - thiadiazole - 5 - sulphonamide. Specifications 577,707 and 867,803 are referred to.
Liver metastases are among the most frequent neoplasms of the liver and represent a quite uniform clinical entity regardless from which carcinoma they originate. The treatment is dependent on number and size of the hepatic lesions but still, none of the therapeutic options leads to satisfying results. The growth of tumors and metastases is dependent on blood vessels, which supply the tumors and metastases with nutrients. Liver metastases, independent from which original tumor they come from, are especially well supplied with blood. The aim of the treatment with the investigational medicinal product EndoTAG®-1 is to target the blood vessels, which supply the metastases, and destroy them. Consequently, the metastases themselves will be damaged.
BACKGROUND: Septic arthritis of shoulder is a rare clinical entity as the metaphysis is extracapsular and there is no communication between epiphyseal and metaphyseal vessels. Septic arthritis of the shoulder joint is a diagnostic and surgical emergency because joint destruction develops rapidly and can cause significant morbidity and mortality. Unusual complications of septic arthritis of the shoulder joint may include extra-articular abscess extension to the upper arm through the biceps groove and osteomyelitis of the greater tuberosity.
CASE PRESENTATION: Septic arthritis of the shoulder, if left untreated, can lead to complications such as extra-articular abscess extension and osteomyelitis. Three patients with septic arthritis of the shoulder joint with no clear history of trauma were reported in this study. The initial presentation was pseudoparalysis with upper arm swelling. MRI diagnosed septic arthritis of shoulder joint together with an upper arm abscess. Arthroscopic debridement with through irrigation and open drainage of the extra-articular abscess extension to the upper arm improved both the shoulder pain and abscess completely. However, if shoulder pain or abnormalities in laboratory findings continue after initial treatment, uncontrolled septic arthritis or secondary osteomyelitis are possibilities that should be concerned. MRI is a useful tool for detecting those atypical complications.
CONCLUSIONS: Rarely, septic arthritis of the shoulder joint can extend to the upper arm through the biceps tendon groove and cause an abscess. Also, acute osteomyelitis of the tuberosity should be considered in patients with long-standing refractory septic arthritis of the shoulder joint who have continued pain and uncontrolled laboratory findings after initial treatment.
Because bupivacaine and meloxicam and their metabolites are excreted by the kidney, the risk of toxic reactions to these drugs may be greater in patients with impaired renal function. This should be considered when performing dose selection of ZYNRELEF. Consider reducing the dose of ZYNRELEF for patients with mild to moderate renal impairment.

Patients with severe renal disease, may be more susceptible to the potential toxicities of the amide-type local anesthetics. Patients with severe renal impairment have not been studied. The use of ZYNRELEF in patients with severe renal impairment is not recommended. Meloxicam is not dialyzable. When using ZYNRELEF in patients on hemodialysis do not exceed maximum recommended dose or use with other meloxicam-containing products [see Clinical Pharmacology (12.3)].
The present invention relates to a (GPR1). The method provides nucleotide sequences of GPR1 genes, and amino acid sequences of their encoded proteins, as well as derivatives (e.g., fragments) and analogs thereof. In a specific embodiment, the GPR1 protein is a yeast protein. The invention further relates to fragments (and derivatives and analogs thereof) of GPR1 which comprise one or more domains of a GPR1 protein. Antibodies to GPR1, its derivatives and analogs, are additionally provided. Methods of production of the GPR1 proteins, derivatives and analogs, e.g., by recombinant means, are also provided. The invention provides for screening assays for identification of compounds that modulate GPR1 expression or activity. Therapeutic methods and pharmaceutical compositions are provided. In specific examples, isolated GPR1 genes and the sequences thereof, are provided.
The invention discloses a preparation method of acid-sensitive degradation-controllable serial polymers with branched structures. The polymers are synthesized from ethylene glycol diglycidyl ether A and a diamine acid sensitive orthoester monomer B serving as frameworks, the molar ratio of A:B is 1-2:1, wherein the structural formulae is shown in the specification. Open loops of epoxy groups at both ends of A are polymerized with amino groups at both ends of B. When the molar ratio of A and B is 1:1, the polymers exist mainly in linear forms. With increase of molar ratio of A, the linear polymers are crosslinked (branched), so that net shapes are formed. When the molar ratio of A:B reaches 2:1, the polymers form three-dimensional netty structures. With increase of molar ratio of A: B, the branching degree of the polymers is improved. The polymers have cations and have the characteristics of acid sensitivity, degradation controllability and good biocompatibility, so that the polymers have important research value and application prospect in the field of gene therapy.
Patients receive either 5FU/LV or Capecitabine, plus BEV. 5FU/LV + BEV is comprised of 5FU IV over 46-48 hours, LV calcium IV over 2 hours, and BEV IV over 10-90 minutes on day 1. Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity. Capecitabine + BEV is comprised of capecitabine PO BID on days 1-14 and BEV IV over 30-90 minutes on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
Sepsis-related brain injury (SRBI) refers to brain dysfunction and structural damage caused by sepsis, which is characterized by inflammation, oxidative stress, and destruction of the blood-brain barrier. Pioglitazone is a PPAR-γ agonist in which PPAR-γ acts as an inflammatory modulator, determining the relationship between PPAR-γ and SRBI and inflammatory state is critical for the disease. This study aimed to construct a drug-target-disease network for SRBI and Pioglitazone based on network pharmacology, and to investigate the therapeutic effect and potential mechanism of Pioglitazone in SRBI induced by lipopolysaccharide (LPS) in rats through transcriptomics. To establish a rat Model of SRBI by intraperitoneal injection of LPS (10 mg/kg): SD rats were divided into Control, Model (LPS), Pioglitazone, (LPS + Pioglitazone) and GW9662 group (LPS+GW9662). The effects and potential mechanisms of Pioglitazone in the treatment of SRBI were studied using biochemical indexes, pathological changes and transcriptome-sequencing (RNA-seq). RNA-seq results showed 620 DEGs between the Model and the Pioglitazone groups. Enrichment analysis involved multiple inflammatory response processes and chemokine receptor binding functions. TLR4 and CXCL10 in the Toll signaling pathway may play an important role in SRBI as important targets. Pioglitazone may ameliorate SRBI through the PPAR-γ/TLR4/CXCL10 pathway.
Perfusion anomalies, namely hypoperfusion of healthy lung and vasoplegia with hyperperfusion of diseased lung areas, have been recently described amongst patients with COVID19. In this triple-blind pilot randomised trial, adult patients with high clinical suspicion of SARS-CoV2 infection and perfusion defects in a substraction computed tomography angiography will be randomised in a 1:1 ratio to receive sildenafil or placebo. Informed consent will be obtained from every included participant. Patients requiring mechanical ventilation at baseline will be excluded, as will those who present a contraindication to sildenafil, previous users of sildenafil, those requiring therapy with nitrates, patients in which an order to limit therapeutic efforts has been issued, pregnant or breastfeeding women and those who decline to participate in this study. The primary outcome for this trial wil be oxygenation changes in blood gas analyses. Secondary outcomes will include clinical deterioration requiring admission to an intensive care unit, requirement of high-flow nasal cannula or invasive mechanical ventilation and overall survival. Patients will be followed-up until hospital discharge or up to fifteen days after randomisation. Statistical analyses will be undertaken by a statistician unaware of treatment allocation under the intention-to-treat principle.
Sinusitis affects 37 million people each year making it one of the most common health problems in the United States. It has a large impact in direct healthcare expenditures, significant loss of workplace productivity and a greater impact on quality of life than diabetes or congestive heart failure.

The most frequently used treatments are medications and/or Functional Endoscopic Sinus Surgery(FESS). 100 subjects undergoing ESS will participate, randomized into two groups, treatment and control. All subjects will have a Nasopore sponge placed into the middle meatus of the nose at the end of the procedure(The sponge is FDA approved and commonly used. Subjects in the treatment group will receive a Nasopore sponge soaked in Bacitracin solution. These subjects will not receive oral antibiotics post-operatively. The control group subjects will have a saline soaked Nasopore sponge laced during surgery and will receive routine oral antibiotics post-operatively. The hypothesis is that subjects who receive the antibiotic soaked nasal sponge in lieu of saline soaked nasal sponge will have infection rates comparable to those who receive systemic antibiotics, but because they will not receive systemic antibiotics, the treated group will have fewer side effects and the cost to treat them will be less.
<P>PROBLEM TO BE SOLVED: To prepare an eye pack cosmetic imparting comfortable and moderate feeling of pressure to eyes and excellent in prevention or improvement of eye trouble or dissolution effect on asthenopia.  <P>SOLUTION: This eye pack cosmetic is composed of a gel sheet part obtained by laminating a gel-like composition onto a support and having a shape simultaneously covering both eyelids and their peripheries and two eye pad parts obtained by impregnating a liquid composition into a nonwoven fabric having a shape covering one eyelid, and the eye pack cosmetic is used by superposing the eye pad part to the gel-like composition surface side of the gel sheet part. In the cosmetic, impregnation amount of the liquid composition is preferably 3-9 times of own weight of the nonwoven fabric. In the cosmetic, the thickness of the nonwoven fabric is preferably 1-5 mm. In the cosmetic, the shape of the nonwoven fabric is preferably elliptical.  <P>COPYRIGHT: (C)2006,JPO&NCIPI
Coronary artery disease (CAD) is a predominant cardiovascular disorder, particularly in the aging population. The pathophysiology of atherosclerosis involves lipid deposition and inflammation of the arterial walls. With coronary computed tomography angiography offering insights into coronary anatomy and pathology, parameters such as pericoronary adipose tissue mean attenuation (PCATMA) have gained significance in the understanding of cardiac diseases. A retrospective study encompassing 130 patients with CAD was conducted to analyze 269 observation points. Coronary CT Angiography was employed, with specific attention paid to the measurement of PCATMA and a qualitative and quantitative assessment of plaques. Statistical analyses were performed using Statistical Package for the Social Sciences software (version 27.0), independent samples t test, one-way ANOVA, and multivariate logistic regression analysis. There was a notable correlation between PCATMA expression and severity of coronary artery calcification and stenosis. Patients with higher coronary artery calcification scores and more pronounced stenosis had elevated PCATMA values. Variances in PCATMA based on plaque type and degree of stenosis were significant (P < .05). Multivariate logistic regression revealed that plaque presence, type, and degree of stenosis were independent determinants of PCATMA expression. PCATMA expression is closely associated with CAD progression. As plaque calcification and arterial stenosis increase, there is a concomitant increase in PCATMA expression, potentially serving as a pivotal prognostic indicator.
Significant data support the hypothesis that HIV-specific cytotoxic T lymphocyte (CTL) responses contribute to the control and potential clearance of the virus. Vaccines designed specifically to induce CTL responses are likely to be well suited for treatment of HIV infection. The conceptual basis of the EP HIV-1090 vaccine is the use of highly defined CTL epitopes as the vaccine immunogen. The vaccine is formulated with a water-soluble polymer that stabilizes and protects the DNA and facilitates uptake by cells. Preclinical studies have shown that the vaccine induces strong CTL responses in animal models. This study will evaluate the safety and tolerability of the vaccine and the immune response to the vaccine in HIV-1-infected individuals who are being treated with highly active antiretroviral therapy (HAART) and have a CD4 count of 350 cells/mm3 or more and fully suppressed viral replication on stable HAART.

Each patient will receive a total of four immunizations to be given at Day 0 and at Weeks 4, 8, and 16. Participants will be randomly assigned to receive either vaccine or placebo. Ten patients will be assigned to each dose group; eight will receive active vaccine and two will receive placebo. The injections will be delivered intramuscularly into the deltoid muscle. In addition to undergoing standard safety exams, patients will have blood drawn for use in evaluating the immunogenicity of the vaccine. The treatment duration will be 16 weeks and patient will be followed for safety and immune responses for an additional 24 weeks after they complete vaccination; the total study is estimated to take 18 months.
This is a prospective, randomized, open label, parallel, 4-month study to explore and evaluate the therapeutic effects of polyethylene glycol loxenatide on the cognitive function, olfactory function, and odor-induced brain activation in T2DM patients with normal cognitive status or MCI inadequately controlled with metformin monotherapy. The control group was treated with Gliclazide. There are 1 principal investigator, 6 sub-investigators and 1 nurse in research centre. The sub-investigators will screen in the outpatient and inpatient departments to enroll 58 patients (29 patients for each arm) totally with the inclusion and exclusion criteria in 9 months. The patients will be randomized at a 1:1 ratio into loxenatide and Gliclazide treatment group with a computer-generated random order. All patients will also continue on their existing dose and regimen of metformin throughout the study. At the baseline, clinical information collection, 100g-steamed bread meal test, biochemical measurement, body composition analysis, cognitive assessment, olfactory test and functional magnetic resonance imaging(fMRI) scan will be conducted for all patients. During the treatment period, visits at 4-week intervals will be performed to evaluate the safety of drugs and adjust the dose of metformin if hypoglycaemia occurs; meanwhile, fasting and 2-hour postprandial plasma glucose assayed by fingerstick, physical examination, and olfactory test will be conducted. At the end of the study, all of the assessments will be performed again for all recruited subjects, including early withdrawal patients.
Micellar Solution comprising DiclofenacThere are provided novel topical or transdermal nano-formulations of diclofenac. The formulations are in the form of micellar solutions. The micellar solutions comprise diclofenac alkali metal salt, in a concentration of about 2% to about 5.5% (w/w), a solvent, a mixture of surfactants, and an aqueous continuous, outer phase. The micellar solution may optionally further comprise permeation enhancers. The micellar solutions can be gelled with a suitable gelling agent. The compositions disclosed are useful in the treatment of joint pain, osteoarthritis, muscle pain, back pain and/or inflammation.